Skip to content

Study · Not a test of the peptide alone · 1990

7 results

Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.

Garaci E, Mastino A, Pica F, Favalli C

Cancer immunology, immunotherapy : CII1 Jan 1990Cited by 42 (Europe PMC)

PMID2126987 (opens in a new tab)PMCIDPMC11038037 (opens in a new tab)DOI10.1007/bf01771450 (opens in a new tab)PepBankPUB-02126987
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with Lewis lung carcinoma, thymosin alpha‑1 followed by interferon alpha/beta after cyclophosphamide produced a rapid disappearance of tumor burden.

    In plain wordsIn mice with lung cancer, thymosin alpha‑1 plus interferon after chemotherapy made the tumors disappear quickly.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor burden after combination chemoimmunotherapy
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with Lewis lung carcinoma, the combination of thymosin alpha‑1 and interferon after cyclophosphamide gave long-term survival in a high percentage of animals, statistically significant versus single agents with chemotherapy or chemotherapy alone.

    In plain wordsIn mice with lung cancer, the combination treatment let many animals live long, more than single drugs with chemotherapy or chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLong-term survival after combination chemoimmunotherapy
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Comparator
    Single agents with chemotherapy, and chemotherapy alone
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself.
    1 context sentence
    Summary · context
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In 3LL tumor-bearing mice given cyclophosphamide, the thymosin alpha‑1 and interferon combination strongly stimulated natural killer activity.

    In plain wordsIn mice with lung cancer, the combination of thymosin alpha‑1 and interferon strongly raised natural killer cell activity.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNatural killer activity after combination chemoimmunotherapy
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Comparator
    Each agent singly
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide
    1 context sentence
    Summary · context
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In 3LL tumor-bearing mice given cyclophosphamide, the thymosin alpha‑1 and interferon combination strongly stimulated cytotoxicity against autologous 3LL tumor cells.

    In plain wordsIn mice with lung cancer, the combination of thymosin alpha‑1 and interferon strongly raised immune killing of the animals' own tumor cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCytotoxicity against autologous 3LL tumor cells after combination chemoimmunotherapy
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Comparator
    Each agent singly
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide
    1 context sentence
    Summary · context
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In 3LL tumor-bearing mice given cyclophosphamide, treatment with each agent singly did not alter or only slightly modified cytotoxic activity towards Yac-1 or 3LL target cells.

    In plain wordsIn mice with lung cancer, each single drug, including thymosin alpha‑1, left killing activity unchanged or only slightly changed.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCytotoxic activity with single agents after cyclophosphamide
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Comparator
    Combination treatment
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells.
    1 context sentence
    Summary · context
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In 3LL tumor-bearing mice, selective antibody depletion showed that killer cells stimulated by the combination treatment bear characteristics of asialo-GM1-positive cells.

    In plain wordsIn mice with lung cancer, the immune killer cells raised by the combination carried the asialo-GM1 marker.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePhenotype of killer cells stimulated by combination treatment
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells.
    1 context sentence
    Summary · context
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In 3LL tumor-bearing mice, tumors from mice treated with the combination chemoimmunotherapy contained a high number of infiltrating lymphoid cells.

    In plain wordsIn mice with lung cancer, tumors from animals given the combination treatment held many infiltrating immune cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLymphoid cell infiltration of tumors after combination treatment
    Study

    mousen: not reported in source

    Lewis lung carcinoma (3LL) tumor-bearing mice
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.
    1 context sentence
    Summary · context
    A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappe…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.